STAT October 9, 2024
Katie Palmer

FDA’s Tala Fakhouri says the agency has so far received nearly 500 submissions with AI components

In the last year, pharma incumbents have leaned into partnerships with AI-driven startups to supercharge drug discovery efforts. High-powered models of protein structure and molecule binding can help identify new disease targets, and even help design new drugs. But AI-derived or not, a new drug candidate still has to wind its way through the painstaking clinical trial process. That is why the pharma industry is also leaning into AI as a tool to...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: AI (Artificial Intelligence), Clinical Trials, FDA, Govt Agencies, Interview / Q&A, Technology, Trends
Related Articles:
Google’s Pixel Watch 3 Loss of Pulse Detection Feature Receives FDA Clearance
FDA Annual Flu Vaccine Meeting and CDC’s ‘Wild to Mild’ Campaign Canceled
Supporting the Development of Drugs for Rare Diseases — The Importance of Regulatory Transparency
Opinion: To fight for those with rare diseases, Trump must reform and modernize the FDA thoughtfully
5 Rare Diseases That Now Have Their First FDA-Approved Treatments

Share This Article